title: Anti-tumour immune effect of oral administration of Lactobacillus plantarum to CT26 tumour-bearing mice.
abstract: Colorectal cancer (CRC) is one of the most prevalent forms of cancer that shows a high mortality and increasing incidence. There are numerous successful treatment options for CRC, including surgery, chemotherapy, radiotherapy and immunotherapy; however, their side effects and limitations are considerable. Probiotics may be an effective strategy for preventing and inhibiting tumour growth through stimulation of host innate and adaptive immunity. We investigated and compared potential anti-tumour immune responses induced by two isolated Lactobacillus strains, Lactobacillus plantarum A and Lactobacillus rhamnosus b, by pre-inoculating mice with lactobacilli for 14 days. Subsequently, subcutaneous and orthotopic intestinal tumours were generated in the pre-inoculated mice using CT26 murine adenocarcinoma cells and were assessed for response against the tumour. Our results indicated that oral administration with L. plantarum inhibited CT26 cell growth in BALB/c mice and prolonged the survival time of tumour-bearing mice compared with mice administered L. rhamnosus. L. plantarum produced protective immunity against the challenge with CT26 cells by increasing the effector functions of CD8+ and natural killer (NK) cell infiltration into tumour tissue, up-regulation of IFN-gamma (but not IL-4 or IL-17) production, and promotion of Th1-type CD4+ T differentiation. Consequently, our results suggest that L. plantarum can enhance the anti-tumour immune response and delay tumour formation.
authors.affiliation: College of Veterinary Medicine, Key Laboratory for Zoonosis Research, Ministry of Education, Institute of Zoonosis, Jilin University, Changchun 130062, China.
authors.forename: Jingtao
authors.initials: J
authors.lastname: Hu
authors.forename: Chunfeng
authors.initials: C
authors.lastname: Wang
authors.forename: Liping
authors.initials: L
authors.lastname: Ye
authors.forename: Wentao
authors.initials: W
authors.lastname: Yang
authors.forename: Haibin
authors.initials: H
authors.lastname: Huang
authors.forename: Fei
authors.initials: F
authors.lastname: Meng
authors.forename: Shaohua
authors.initials: S
authors.lastname: Shi
authors.forename: Zhuang
authors.initials: Z
authors.lastname: Ding
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy; D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000628:therapy*; D005260:Female; D007694:Killer Cells, Natural / Q000276:immunology; D048191:Lactiplantibacillus plantarum; D052201:Lacticaseibacillus rhamnosus; D051379:Mice; D008807:Mice, Inbred BALB C; D019936:Probiotics / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents